Browse studies

Find your next paid study

3,843 recruiting studies matching your filters

RASolute 305: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (Modified FOLFIRINOX or Gemcitabine Plus Nab-Paclitaxel) With or Without Zoldonrasib (RMC-9805) as First-line Treatment in Patients With Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma

The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared to placebo…

Pancreatic CancerPancreatic Cancer MetastaticPDAC+5 more

Estimated

~$10 – $8,750

Revolution Medicines, Inc.NCT07621718

Observational

Cancer Oriented Understanding and Navigation Via Supportive and Educational Language Models (COUNSEL)

A randomized, open-label behavioral study designed to evaluate the feasibility, acceptability, and early impact of a large language model (LLM)-based artificia…

Prostate CancerProstatic NeoplasmsPatient Education as Topic

Estimated

~$10 – $5,625

University of California, San FranciscoNCT07836933

Phase 1

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

Background: Each year, more than 32,000 people in the United States are diagnosed with colorectal cancer that has returned or progressed after treatment and s…

Metastatic Colorectal Cancer

Documented

$500/visit

National Cancer Institute (NCI)NCT06149481

Phase 3

PADL1NK-005: A Randomized, Phase 3, Open-Label Study to Evaluate PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lun…

Non-small Cell CarcinomaNon-Small Cell Lung Cancer MetastaticNon-Small Cell Lung Carcinoma

Single-Dose Stereotactic Radiosurgery (SDRT) as Definitive Non-Operative Treatment for Early-Stage Breast Cancer: A Prospective Single-Arm Pilot Trial With Bayesian Safety Monitoring (SOLIS / Protocol RAD 2024)

SOLIS is a prospective, single-arm, single-institution pilot trial evaluating single-fraction stereotactic radiotherapy (24 Gy to the planning target volume wi…

Breast CancerEarly-Stage Breast CarcinomaHormone Receptor-Positive Breast Cancer+1 more

Estimated

~$10 – $7,500

Renaissance Institute of Precision Oncology and RadiosurgeryNCT07844759

Phase 2

MINTER Trial: Metal Intervention aNd ThErapy With Radiotherapy In Thoracic Cancer Using Copper Donor Therapy: A Phase 2, Open-Label Study

This study is being done to test whether adding two drugs-disulfiram and copper gluconate-to radiation therapy can help overcome this resistance and improve tr…

Thoracic Cancer

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT07843537

Phase 3

An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole Versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease

The purpose of this study is to investigate the efficacy and safety of BGB-43395 in combination with letrozole compared with investigator's choice of cyclin-de…

HR+/HER2- Breast Cancer

Estimated

~$10 – $7,500

BeOne MedicinesNCT07492641

Phase 1

A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants With Advanced HER2+ Solid Tumors

This study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and…

Breast CancerGastric CancerGastroesophageal-junction Cancer

Estimated

~$10 – $8,750

Iksuda Therapeutics Ltd.NCT05872295

Phase 2

A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in Patients With Metastatic Cancer

Background: A person s tumor is studied for mutations. When cells are found that can attack the mutation in a person s tumor, the genes from those cells are s…

Endocrine TumorsNon-Small Cell Lung CancerOvarian Cancer+4 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT03412877

Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome

Background: A germline mutation is a change to a person s genes that is carried through their DNA. These mutations can be passed on from parents to their offs…

Familial CancerBRCA1-Associated Protein-1 (BAP1) MutationsTumor Predisposition Syndrome (TPDS)+1 more

Estimated

~$10 – $675

National Cancer Institute (NCI)NCT04431024

Observational

RSMI HEALS (Health Equity Advances Through Language Solutions) (AI)

The study will be conducted in 2 overlapping phases. In Phase 1, there will be a 3-arm randomized controlled trial of Remote Simultaneous Medical Interpreting/…

Breast CancerBreast Cancer Stage IIBreast Cancer Stage III

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT06721065

Phase 1

A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)

To find out if the combination of HC-7366 and nivolumab (with or without ipilimumab) can help to control ccRCC. The

Phase 1bHC-7366SHARK+1 more

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT07401875